Delivering Strong and Sustainable Performance

Fourth-quarter 2019 sales worldwide

$8.3 billion

+8.5%1 on organic basis

Sales performance across Abbott—on organic basis2

+11.3% medical devices

+6.4%2 diagnostics

+5.8% nutrition

+10.0% established pharmaceuticals

Full-year 2019 sales worldwide

$32 billion

+7.7%3 on organic basis

Full-year 2019 financial results

* Organic sales growth excludes the results for a non-core business within U.S. adult nutrition during the first nine months of 2018 as this business was discontinued during the third quarter of 2018; and excludes the impact of foreign exchange. For full financial data and reconciliation of non-GAAP measures, please see our press release dated January 22, 2020, available at www.abbottinvestor.com.

† Data on file, Abbott Diabetes Care. Data based on the number of users worldwide for the FreeStyle Libre system compared to the number of users for other leading personal use, sensor-based glucose monitoring systems.

1. On a GAAP basis, fourth-quarter Abbott sales increased 7.1%.
2. On a GAAP basis, medical devices sales increased 9.7%; diagnostics sales increased 5.0%; nutrition sales increased 5.2%; and established pharmaceuticals sales increased 7.8%.
3. On a GAAP basis, full-year Abbott sales increased 4.3%.
4. Adjusted diluted EPS excludes specified items. On a GAAP basis, full-year diluted EPS guidance is $2.35 to $2.45. Abbott has not provided the GAAP financial measure for organic sales growth on a forward-looking basis because the company is unable to predict the impact of foreign exchange due to the unpredictability of future changes in foreign exchange rates, which could significantly impact reported sales growth.
5. On a GAAP basis, medical devices sales increased 10%.
6. On a GAAP basis, MitraClip and FreeStyle Libre sales increased 27% and 59%, respectively.
7. On a GAAP basis, core laboratory diagnostics sales increased 8.4%.
8. On a GAAP basis, established pharmaceuticals sales increased 7.8%.

For forward-looking statements:

Some statements in this communication may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, “Risk Factors,” to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended December 31, 2018, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

Our branded generics strategy in emerging markets continues to be highly successful. Sales performance was led by growth across several countries in Latin America and Asia.